Terazosin Capsule
Product Images NDC 70518-3193

This text appears to be a chemical formula. It includes the elements Carbon (C), Hydrogen (H), Oxygen (O), and Nitrogen (N) along with Hydrochloric acid (HCl) and its molecular weight. However, the format is not in a readable manner, and it is difficult to determine the specifics of the chemical formula. Thus, a useful description cannot be provided.*

The text appears to be a table showing Symptom Score and Peak Flow Rate of patients who participated in three different studies on the effect of Terazosin. The studies involved different dosages of Terazosin (ranging from 1 mg to 20 mg) and were compared to Placebo. The table shows mean values of the Symptom Score and Peak Flow Rate at Baseline and after Treatment for both Terazosin and Placebo groups, along with the percentage change. The table also highlights that the highest dose of 10 mg showed the most significant improvement in patients.*

The text describes a figure labeled "Figure 1" and data from "Study 1" measuring the mean change in total symptoms and peak flow rate from baseline for two groups: placebo and terazosin. The data is presented in a graph with three months on the x-axis and units of mL/sec and symptom score on the y-axis. The terazosin group shows a statistically significant increase in peak flow rate compared to the placebo group. No additional information is available.*

The figure shows the mean change in the total symptom score from baseline in a long-term, open-label, non-placebo controlled study with a sample size of 494. The mean change from baseline is presented for months 0 to 30, with statistically significant differences (* p <0.05) compared to baseline (mean baseline = 10.7).*

The figure shows the mean change in peak flow rate from baseline in a long-term, non-placebo controlled study involving 494 participants. The peak flow rate is measured in mL/sec, and the results are presented graphically over a period of 30 months. The mean baseline is 9.9, and statistical significance is indicated by asterisks.*

This is a report on mean changes in blood pressure from baseline to final visit in double-blind placebo-controlled studies on normotensive and hypertensive patients. The report includes the SBP and DBP in mmHg for both patient groups. The report consists of a table with patient numbers and their mean changes. The study includes a placebo group and a Terazosin group. The text states that the Terazosin group showed statistically significant lower mean changes in blood pressure compared to the placebo group.*

This is a table depicting adverse reactions during placebo-controlled trials related to Benign Prostatic Hyperplasia using Terazosin medication. The table displays the type of adverse reaction along with the percentages of occurrence being compared between Terazosin and Placebo groups. The adverse reactions observed in the body systems such as cardiovascular system, nervous system, respiratory system, etc are listed. The comparison shows that for some reactions such as Syncope, Postural Hypotension, Nasal Congestion, Impotence, and Dizziness, Terazosin seems to have more adverse reactions than Placebo while for other reactions such as Nausea, Weight Gain, and Urinary Tract infection, Placebo seems to have more adverse reactions than Terazosin.*

This is a table presenting the rates of discontinuation due to adverse events during a placebo-controlled trial for benign prostatic hyperplasia. The table lists different body systems and the percentages of participants who discontinued the trial due to adverse events related to that body system for both the group that received terazosin (N=636) and the group that received a placebo (N=360). Adverse events reported included fever, headache, postural hypotension, syncope, nausea, dizziness, vertigo, dyspnea, blurred vision/amblyopia, and urinary tract infections.*

This is a table displaying adverse reactions during placebo-controlled trials of the drug Terazosin. The table contains adverse reactions organized by body systems, including hypertension, cardiovascular system, respiratory system, and more. The percentage of patients who experienced each adverse reaction is listed for both the Terazosin and placebo groups. The table notes that "asthenia" refers to weakness, tiredness, lassitude, and fatigue. Some adverse reactions were statistically significant at the 0.05 level.*

This is a table displaying discontinuation rates in patients during placebo-controlled trials for hypertension medication Terazosin versus placebo. The table shows the percentage of patients that experienced various side effects that caused them to discontinue treatment, categorized by bodily system or symptom. Most common side effects were asthenia, headache, and dizziness.*

Terazosin is a medication available in 1mg capsules, with a quantity of 30, manufactured by Avet Pharmaceuticals Inc., East Brunswick, NJ. Its NDC (National Drug Code) is 70518-3193-00, and it has an expiration date and a LOT number. The medication should be kept out of the reach of children, and it is necessary to see the package insert for directions on how to use it. It should be stored at 20-26°C (63-77°F), with excursions permitted to 15-30°C (59-86°F) and is repackaged by RemedyRepack Inc., Indiana, PA 15701, 724.465.8762.*